As most patients have disease flares with GC tapering and require prolonged treatment, steroid sparing agents have been sought, with methotrexate identified as providing benefit in PMR and likely some in GCA, and targeted blockade of IL-6R with tocilizumab (TCZ) providing benefit in GCA. Here, IL6R is linked to temporal arteritis.